Bunge isn't merely a grain trader—it's one of the world's most important agricultural infrastructure companies. After a 43% rally from our 2025 recommendation, a healthy pullback, another insider purchase, stronger earnings guidance and accelerating Viterra synergies make the long-term investment story compelling once again.

Read entire article

Huntsman isn't simply a cyclical chemical company anymore. Between repeated insider buying, a transformational $12.5 billion merger with Olin, trading at just 0.64x book value and more than $400 million in projected synergies, investors may be looking at one of the market's more intriguing industrial turnaround opportunities.

Read entire article

Exactly one year after publishing our original bullish thesis on Elevance Health, we're revisiting the story. Shares are up nearly 26%, yet the core investment case remains surprisingly intact. CEO Gail Boudreaux just bought another $1 million worth of stock, institutions continue to hold over 93% of shares, and valuation still looks attractive.

Read entire article

Is Occidental Petroleum one of the market's most misunderstood value stocks? With Warren Buffett owning more than a quarter of the company, a brand-new CEO buying shares, $7.1 billion of debt retired, and a carbon-capture business quietly emerging, OXY may be much more than just another oil producer.

Read entire article